Definitive Contract 75A50120C00177
Award Date
9/28/20
Potential Completion Date
12/31/31
Potential Value
$114M
Awardee
Vedanta Biosciences, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
Boston, MA 02116, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract focuses...
This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...
This contract, awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), provides $167,067,962.00 to Venatorx Pharmaceuticals Inc. to develop new antibiotics to treat drug-resistant gram-negative bacteria, including public health pathogens. The contract, which has a definitive, cost-sharing pricing structure, supports Venatorx's research and development of novel anti-infective therapeutics, with the goal...
This contract award, valued at $32,666,134.00, was issued by the Department of Health and Human Services' (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Invirsa, Inc. for the advanced research and development of INV-102, a treatment for mustard gas keratopathy, under Broad Agency Announcement (BAA) BAA-18-100-SOL-00003. The contract does not have a set-aside designation. The original BAA solicited proposals for the development of medical countermeasures against...
This is a $28,613,040.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Crestone, Inc., a biotech company specializing in research on treatments for antibiotic-resistant bacterial infections. The contract supports Crestone's work to synthesize antibiotic compounds, test their activity, and advance lead candidates through investigational new drug filing and early...
This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
This federal contract award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Inflammatix, Inc., a small disadvantaged business. The $749,999 firm fixed-price contract supports research and development for the Triverity cartridge, a diagnostic tool focused on infection severity and sepsis detection, under Area of Interest #2 of ASPR's Easy Broad Agency Announcement. The...
The U.S. Department of Health and Human Services (HHS), through the Office of the Assistant Secretary for Preparedness and Response (ASPR), has awarded a $43,544,163 Firm Fixed Price contract to Biofire Defense LLC to advance the development of the Reveal Rapid Antibiotic Susceptibility Test (AST) System as an diagnostic countermeasure for life-threatening urgent infections. This contract, which runs through December 31, 2026, stems from a Broad Agency Announcement issued by BARDA in 2017...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Radix Biosolutions LLC, a small business manufacturer of diagnostic assay kits. The $910,522.80 cost-plus-fixed-fee contract supports the development of "A MULTIPLEXED DIAGNOSTIC IMMUNOASSAY FOR CLOSTRIDIUM DIFFICILE AND ANTIBIOTIC-ASSOCIATED DIARRHEA". The award has a performance period ending on September 13, 2018....